60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ:SXTP
Want to see SXTP full AI Analyst Report?
SXTP Stock Chart & Stats
$0.50
-$0.08(-5.71%)
At close: 4:00 PM EST
$0.50
-$0.08(-5.71%)
Day’s Range― - ―
52-Week Range$1.22 - $10.77
Previous CloseN/A
Volume13.44M
Average Volume (3M)199.18K
Market Cap
$4.49M
Enterprise Value-$1.88M
Total Cash (Recent Filing)$3.34M
Total Debt (Recent Filing)$151.97K
Price to Earnings (P/E)―
Beta2.44
Next Earnings
Aug 19, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.15
Shares Outstanding2,659,288
10 Day Avg. Volume488,900
30 Day Avg. Volume199,179
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.39
Price to Sales (P/S)1.35
P/FCF Ratio-0.19
Enterprise Value/Market Cap-0.42
Enterprise Value/Revenue-1.87
Enterprise Value/Gross Profit-8.95
Enterprise Value/Ebitda0.25
Forecast
1Y Price Target
$3.70Price Target Upside640.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.16
Revenue Forecast (FY)$1.30M
Bulls Say, Bears Say
Bulls Say
Specialty Infectious-disease FocusA concentrated business model in infectious diseases and marketed malaria therapeutics gives 60 Degrees a durable niche with specialized regulatory and commercial expertise. This focus supports repeatable product development, clearer go-to-market paths in endemic and travel markets, and long-term market positioning independent of short-term volatility.
Patent Licensing For Scale-upSecuring a license to scale production of castanospermine is a structural step to control supply and enable non-prescription product lines. Verticalizing manufacturing reduces reliance on third parties, supports margin improvement over time, and creates optionality to diversify revenue outside prescription malaria therapies.
Low Leverage And Positive EquityA low-debt balance sheet and positive equity reduce near-term bankruptcy risk and preserve financial flexibility. This foundation supports the company’s ability to pursue trials, regulatory filings, or partnerships without the immediate drag of interest service, improving resilience over the medium term.
Bears Say
High Cash BurnSustained negative operating and free cash flow at this magnitude creates structural runway pressure and forces recurring external financing. Over 2–6 months this reduces strategic optionality, risks dilutive financings ahead of major milestones, and constrains investment in commercialization or new development programs.
Small, Declining Revenue And Large LossesA very small and declining revenue base combined with large, persistent losses indicates weak commercial traction and an unproven ability to scale. Even with gross margin improvement, operating losses mean the company remains dependent on financing and clinical/regulatory successes to achieve sustainable profitability.
Potential Dilution & Disclosure RiskReliance on ATM or equity financing as signaled by the legal opinion creates a durable dilution risk that can erode shareholder value as trials progress. Coupled with a recent correction to affiliate share disclosure, these governance and financing factors can weaken investor confidence and complicate long-term capital planning.
60 Degrees Pharmaceuticals, Inc. News
SXTP FAQ
What was 60 Degrees Pharmaceuticals, Inc.’s price range in the past 12 months?
60 Degrees Pharmaceuticals, Inc. lowest stock price was $1.22 and its highest was $10.77 in the past 12 months.
What is 60 Degrees Pharmaceuticals, Inc.’s market cap?
60 Degrees Pharmaceuticals, Inc.’s market cap is $4.49M.
When is 60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date?
60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 56 days.
How were 60 Degrees Pharmaceuticals, Inc.’s earnings last quarter?
Currently, no data Available
Is 60 Degrees Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts 60 Degrees Pharmaceuticals, Inc.’s price is currently Undervalued.
Does 60 Degrees Pharmaceuticals, Inc. pay dividends?
60 Degrees Pharmaceuticals, Inc. does not currently pay dividends.
What is 60 Degrees Pharmaceuticals, Inc.’s EPS estimate?
60 Degrees Pharmaceuticals, Inc.’s EPS estimate is -0.74.
How many shares outstanding does 60 Degrees Pharmaceuticals, Inc. have?
60 Degrees Pharmaceuticals, Inc. has 2,659,288 shares outstanding.
What happened to 60 Degrees Pharmaceuticals, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of 60 Degrees Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in SXTP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
SXTP Stock 12 Month Forecast
Average Price Target
$3.70
▲(640.00% Upside)
Technical Analysis
Ownership Overview
1.08% Insiders
0.33% Mutual Funds
5.44% Other Institutional Investors
93.15% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---